GlassScriptPhysician profile
David M Sharfman
NPI 1972588457
$1,788.80
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,700 · 2024: $88.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $88.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $88.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $346.98 | 2019-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $231.38 | 2019-2024 | Farxiga |
| Amarin Pharma, INC. | $184.84 | 2019 | |
| Pfizer INC. | $156.14 | 2019 | |
| Janssen Pharmaceuticals, INC | $150.44 | 2019 | |
| Lilly USA, LLC | $147.29 | 2019 | |
| Astellas Pharma US INC | $112.77 | 2019-2024 | Veozah |
| Glaxosmithkline, LLC. | $84.56 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.69 | 2019 | |
| Sanofi-Aventis U.S. LLC | $67.10 | 2019 | |
| Amgen INC. | $62.23 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.35 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $27.83 | 2019 | |
| Sunovion Pharmaceuticals INC. | $27.23 | 2019 | |
| Mylan Specialty L.P. | $14.63 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $13.25 | 2019 | |
| Abbvie INC. | $11.25 | 2019 | |
| Merck Sharp & Dohme LLC | $11.03 | 2019 | |
| Acadia Pharmaceuticals INC | $10.93 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sharfman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.